CalBot is Theranautilus' flagship nanorobotic platform developed to treat dental hypersensitivity by addressing its root cause. Using magnetically maneuverable nanobioceramic nanorobots, CalBot navigates deep into exposed dentinal tubules to create durable biomineralized seals, providing targeted and long-lasting relief. Unlike conventional desensitizing treatments that offer temporary benefits, CalBot is designed to restore tooth integrity while protecting against future deterioration. The technology has successfully completed preclinical validation and is advancing toward human clinical studies.

Theranautilus is developing a non-invasive nanorobotic platform for the treatment of peri-implantitis, a leading cause of dental implant failure. By combining magnetic navigation with targeted therapeutic action, the technology is designed to disrupt bacterial biofilms surrounding implants without invasive surgery. This innovative approach aims to improve implant longevity, reduce patient discomfort, and transform implant maintenance into a preventive and precision-driven solution.

Theranautilus is also advancing the development of next-generation dental materials designed to overcome limitations associated with traditional restorative products. The company is developing what it believes to be the world's first tunable dental cement platform capable of controlled placement and adaptation within microscopic defects of tooth structures. By combining advanced biomaterials engineering with nanotechnology principles, these materials are intended to improve restoration quality, durability, and clinical outcomes. Initial materials research has been completed, and future studies will focus on preclinical validation and translational development. The project is being pursued in collaboration with government-supported technology initiatives and represents an important expansion of the company's oral healthcare portfolio.

Building on its nanorobotics platform, Theranautilus is expanding into oncology to address challenges in cancer diagnosis and treatment. By integrating precision navigation, localized sensing, and targeted therapeutic capabilities, the platform aims to improve tumor detection, enhance treatment accuracy, and enable minimally invasive interventions. These technologies are being developed to support the next generation of precision oncology.

One of the most promising applications of the oncology platform involves assisting surgeons in identifying and delineating tumor boundaries with greater accuracy. Nanorobots can potentially be used to detect microscopic disease regions that are difficult to visualize using conventional imaging methods. This capability could support improved surgical planning, enhance tumor removal accuracy, and reduce the likelihood of residual disease following surgery. Current development efforts include prototype devices and controlled animal studies focused on brain, peritoneal, and other solid tumors.

The company's targeted drug delivery platform utilizes magnetically controlled nanorobots to transport therapeutic agents directly to diseased tissues. By improving drug localization and tissue penetration while reducing systemic exposure, the technology has the potential to enhance treatment effectiveness and minimize side effects, particularly in oncology and other complex diseases.

Theranautilus is exploring nanorobotic technologies for localized therapeutic intervention within tumors. Through controlled navigation and targeted activation, these systems aim to deliver precise treatment while minimizing damage to surrounding healthy tissue. Currently in preclinical development, this platform represents a promising advancement toward safer and more effective precision cancer therapies.